Toronto-based Analytics 4 Life has raised a $25 million USD Series B to support its mission of using AI to disrupt medical imaging.
The round was led by an international syndicate of accredited investors, including physicians, healthcare professionals, and medical device experts.
The company’s cardiac imaging technology is under clinical investigation. This technology, called CorVista, is meant to help physicians assess the presence of coronary artery disease (CAD) using intrinsic signals scanned from the body without radiation, contrast agents, or cardiac stress.
“Heart disease is the leading cause of death globally, with one in 7 deaths in the US attributed to CAD. We are thankful for the continued support from passionate investors who have made it possible for us to revolutionize the way that CAD is diagnosed,” said Don Crawford, CEO of Analytics 4 Life. “Securing this oversubscribed financing fuels our rapid growth to advance development of our diagnostic tool and gives us the resources we need to deliver this game-changing technology to patients and physicians.”
CoVista scans signals naturally emitted by the body with a synchronous array of seven sensors on a collection device. After the signals are acquired, the signal package is instantaneously transmitted to the cloud, where it is analyzed by a machine-learned algorithm to generate a heart model indicating areas of potential heart disease. Results of the test are then displayed on a secure physician web portal combined with a patient’s medical history, risk factors, and symptoms.
Investor Aaron Berez has also joined the company’s board of director. Berez is the founder and CEO of Alembic, and past co-founder of Chestnut Medical, which was acquired by Ev3 and now operates under Medtronic.
Photo via Unsplash
